December 17, 2004 -- The surprising news on AstraZeneca’s Iressa is the latest in a series of setbacks for the company, and it sent the company’s stock lower by 9% in midday trading today, with volume about twice the normal level. Will AstraZeneca be withdrawn? We don’t think so, but the bad news for AstraZeneca was clearly good news for competitors Genentech and OSI Pharmaceuticals. We look at their prospects, plus AstraZeneca’s problems...
